dcSSc, Diffuse Cutaneous Systemic Sclerosis, Scleroderma
Conditions
Keywords
Diffuse Cutaneous Systemic Sclerosis (dcSSc), Phase 1/2 clinical trial, dose escalation randomized trial, Brentuximab vedotin
Brief summary
There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activated immune cells There is evidence for CD30 involvement in SSc. This study represents the first step in determining safety and tolerability of brentuximab vedotin in SSc.
Detailed description
This is a multicenter prospective double blind placebo controlled dose escalation safety clinical trial with brentuximab vedotin and stable background immunosuppressive therapy in adult individuals with Diffuse Cutaneous Systemic Sclerosis (dcSSc). Adult male and female participants with dcSSc will be recruited by a collaborative group of clinical sites in the United States. Participants who meet the eligibility criteria will be enrolled without regard to gender, race, or ethnicity. Eligible participants will be randomly assigned to study treatment, either brentuximab vedotin or placebo equivalent in a 6:2 ratio favoring brentuximab vedotin. Three dose cohorts are planned with 8 participants in each cohort, for a total of 24 participants who receive sufficient doses of the investigational medication to assess safety. The doses planned for each ascending dose cohort include 0.6mg/kg, 1.2 mg/kg, and 1.8 mg/kg brentuximab vedotin or placebo equivalent. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses. Following completion of treatment, participants will undergo follow-up visits at weeks 24, 28, 36 and 48.
Interventions
BIOLOGICALBrentuximab Vedotin
Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
BIOLOGICALPlacebo
Placebo control for blinding (masking), 0.95% normal saline.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN)
Seagen Inc.
PPD Development, LP
Rho Federal Systems Division, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Classification of Systemic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/European Union League Against Rheumatism classification of SSc; * Diagnosis of Diffuse Cutaneous Systemic Sclerosis (dcSSc), as defined by LeRoy and Medsger, Criteria for the classification of early systemic sclerosis. J Rheumatol, 2001. 28(7): p. 1573-6; * Disease duration ≤ 60 months (defined as time from the first non-Raynaud phenomenon manifestation); * Modified Rodnan Skin Score (mRSS) units ≥ 15 and ≤ 45, and both of the following: * At least mild skin thickening (≥ 1+ mRSS) of the forearm, and * At least moderate skin thickening (≥ 2+ mRSS) at the planned forearm skin biopsy site. * Documentation of at least 12 weeks of ongoing immunosuppressive therapy for SSc at the time of enrollment, and at least 4 weeks at a stable dose, of one of the following: * Methotrexate ≤ 25 mg/week, or * Mycophenolate mofetil ≤3 grams/day or mycophenolate sodium ≤2.16 grams/day, or * Azathioprine ≤3mg/kg/day. * Ability to provide informed consent.
Exclusion criteria
* Rheumatic disease other than Diffuse Cutaneous Systemic Sclerosis (dcSSc); it is acceptable to include patients with osteoarthritis, fibromyalgia, sicca symptoms, and scleroderma-associated myopathy; * Limited cutaneous Systemic Sclerosis (SSc) or sine scleroderma; * Pulmonary disease with Forced Vital Capacity (FVC) ≤60% of predicted, or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) (corrected for hemoglobin) ≤60% of predicted; * Pulmonary hypertension (PH) or moderate to severe left ventricular dysfunction, defined as one of the following: * Transthoracic echocardiography demonstrating at least one of the following (unless subsequent right heart catheterization does not demonstrate PH; or unless prior right heart catheterization within one year did not demonstrate PH and echocardiography results are not significantly changed): * Tricuspid regurgitation jet \>2.8 m/sec or estimated right ventricular systolic pressure \> 42 mm Hg. or * At least one of the following: 1. Abnormality of right atrial size, shape, or wall thickness consistent with PH, or 2. Abnormality of right ventricular size, shape, or wall thickness consistent with PH, or 3. Abnormal septal wall shape consistent with PH. * Left Ventricular Ejection Fraction (LVEF) \<50%. * Right heart catheterization showing mean pulmonary artery pressure ≥25 mm Hg at rest; * Current use of approved medications for PH. It is acceptable to use phosphodiesterase type 5 (PDE-5) inhibitors for Raynaud's, digital ulcers, and intermittently for erectile dysfunction. * Active scleroderma renal crisis within the 4 months prior to enrollment; * History of moderate-to-severe lower gastrointestinal dysmotility such as current use of parenteral nutrition and/or recent history of intestinal pseudo-obstruction within 3 months prior to enrollment; * The following medications: * Oral corticosteroids \>10 mg/day of prednisone or equivalent within 2 weeks prior to enrollment; * Treatment with Intravenous Immunoglobulin (IVIG) within 12 weeks prior to enrollment; * Treatment with cyclophosphamide within 6 months prior to enrollment; * Use of investigational biologic or non-biologic medication within the past 90 days, or 5 half-lives prior to enrollment, whichever is greater; * Use of anti-TNF medication or other biologic medications within the past 90 days, or 5 half-lives prior to enrollment, whichever is greater; * Prior treatment with anti-CD20 if either of the following are true: * B cells ≤ lower limit of normal (LLN), or * Treatment with anti-CD20 has been within 12 months prior to enrollment. * Any prior treatment with cell-depleting therapies other than anti-CD20, including investigational agents, including but not limited to, CAMPATH(R), anti- CD4, anti-CD5, anti-CD3, anti-CD19; or * Any prior treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation. * Receipt of a live-attenuated vaccine within 3 months of study enrollment; * Concomitant malignancies or a history of malignancy, with the exception of adequately treated basal and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix; * Major surgery (including joint surgery) within 8 weeks prior to enrollment; * History of solid organ or hematopoietic stem cell transplantation; * History of primary immunodeficiency; * Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to enrollment; * Current substance abuse or history of substance abuse within 12 months prior to enrollment; * History of severe depression or severe psychiatric condition; * Lack of peripheral venous access; * Known hypersensitivity to brentuximab vedotin, a component thereof, or the excipient contained in the drug formulation; * Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease (or, in the investigator's opinion, any other concomitant medical condition that places the participant at risk by participating in this study), including but not limited to: * Uncompensated congestive heart failure (New York Heart Association Class III or VI); * Clinically significant active coronary artery disease (e.g., unstable angina or acute myocardial infarction within 6 months prior to enrollment); * Recently active cerebrovascular disease (e.g., stroke or transient ischemic attack within 6 months prior to enrollment); * Uncontrolled systemic hypertension; * Confirmed diagnosis of diabetes mellitus; * Pancreatitis within 30 days prior to enrollment; or * History or presence of peripheral neuropathy, such as mononeuritis multiplex, acute or chronic inflammatory demyelinating polyneuropathy, axonal sensorimotor neuropathies, or drug related neuropathy or neuritis. * Evidence of infection: * Any infected ulcer at enrollment; * Active bacterial, viral, fungal, or opportunistic infections requiring systemic anti-infective therapy; * Evidence of current or prior infection with tuberculosis: * Positive QuantiFERON® - TB Gold or TB Gold Plus test results. * Note: Purified protein derivative (PPD) tuberculin test may be substituted for QuantiFERON® - TB Gold or TB fold Plus test. * Indeterminant QuantiFERON® - TB Gold test results, unless followed by a subsequent negative PPD or negative QuantiFERON® and clearance by local Infectious Disease department. * Evidence of current or prior infection with: * Human Immunodeficiency Virus (HIV), or * Hepatitis B Virus (as assessed by hepatitis B surface antigen, HBsAg and antibody to hepatitis B core antigen, anti-HBc), or * Hepatitis C Virus (HCV), with the exception of adequately treated HCV with documentation of sustained virologic response, defined as undetectable HCV RNA at least 12 weeks after the end of treatment. * History of progressive multifocal leukoencephalopathy (PML); * Hospitalization for treatment of infections, or parenteral (intravenous or intramuscular) antibacterials, antivirals, anti-fungals, or anti-parasitic agents within the past 60 days prior to enrollment; * Chronic infection that is currently being treated with systemic suppressive antibiotic or antiviral therapy, including but not limited to tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, and atypical mycobacteria. * History of significant infection or recurrent infection that, in the investigator's opinion, places the participant at risk by participating in this study. * Positive polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) within 14 days prior to enrollment. * The following laboratory abnormalities: * Neutropenia (absolute neutrophil count \<1500/mm\^3); * Thrombocytopenia (platelets \<100,000/mm\^3); * Moderately severe anemia (hemoglobin, Hgb \< 10 g/dL); * Liver function test (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], or alkaline phosphatase) results that are ≥ 1.5 times the upper limit of normal; * Serum total bilirubin \> 1.5 times the upper limit of normal, or \> 3 times the upper limit of normal in the presence of Gilbert's syndrome; or * Serum amylase and serum lipase \> 1.5 times the upper limit of normal. * Renal dysfunction, defined as either one of the following: * Serum creatinine \> 1.5 times the upper limit of normal; or * Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m\^2. * Pregnancy; * Breastfeeding; * Unwillingness to use two forms of medically acceptable contraception methods by participants and their partners (if of reproductive potential) during the study and for at least 6 months after last dose of study drug; or * Inability to comply with study and follow-up procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | Baseline through end of study (48 weeks for participants who complete the study) | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Baseline through Week 12 study visit or 12 weeks on study if the visit was missed. Baseline through Week 24 study visit or 24 weeks on study if the visit was missed. Baseline through Week 36 study visit or 36 weeks on study if the visit was missed | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | Baseline through Week 12 study visit or 12 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | Baseline through Week 24 study visit or 24 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | Baseline through Week 36 study visit or 36 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
| Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. |
| Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed. | Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin. |
Countries
United States
Contacts
STUDY_CHAIRDinesh Khanna, MD, MSc
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
STUDY_CHAIRDavid Fox, MD
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 Brentuximab Vedotin Participants receive intravenous administration of 0.6 mg/kg Brentuximab Vedotin every 3 weeks for 21 weeks, for a total of 8 doses. | 6 |
| Cohort 1 Placebo Participants receive intravenous administration of 0.9% Normal Saline solution every 3 weeks for 21 weeks, for a total of 8 doses. | 2 |
| Cohort 2 Brentuximab Vedotin Participants receive intravenous administration of 1.2 mg/kg Brentuximab Vedotin every 3 weeks for 21 weeks, for a total of 8 doses. | 7 |
| Cohort 2 Placebo Participants receive intravenous administration of 0.9% Normal Saline solution every 3 weeks for 21 weeks, for a total of 8 doses. | 2 |
| Total | 17 |
Baseline characteristics
| Characteristic | Cohort 1 Brentuximab Vedotin | Cohort 1 Placebo | Cohort 2 Brentuximab Vedotin | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants | 2 Participants | 7 Participants | 2 Participants | 16 Participants |
| Age, Continuous | 48.0 years STANDARD_DEVIATION 16.52 | 42.0 years STANDARD_DEVIATION 22.63 | 53.1 years STANDARD_DEVIATION 7.97 | 47.0 years STANDARD_DEVIATION 7.07 | 49.3 years STANDARD_DEVIATION 12.59 |
| Baseline Modified Rodnan Skin Score (mRSS) Total Score | 31.3 Score STANDARD_DEVIATION 6.53 | 24.5 Score STANDARD_DEVIATION 2.12 | 29.0 Score STANDARD_DEVIATION 11.58 | 19.5 Score STANDARD_DEVIATION 2.12 | 28.2 Score STANDARD_DEVIATION 8.9 |
| Body Mass Index (BMI) | 26.73 kg/m^2 STANDARD_DEVIATION 5.397 | 32.49 kg/m^2 STANDARD_DEVIATION 0.939 | 26.37 kg/m^2 STANDARD_DEVIATION 4.831 | 22.21 kg/m^2 STANDARD_DEVIATION 0.784 | 26.73 kg/m^2 STANDARD_DEVIATION 4.971 |
| Disease Duration from Onset of Non-Raynaud's Symptoms | 17.5 Months STANDARD_DEVIATION 6.7 | 46.4 Months STANDARD_DEVIATION 8.43 | 19.0 Months STANDARD_DEVIATION 8.65 | 26.2 Months STANDARD_DEVIATION 14.98 | 22.5 Months STANDARD_DEVIATION 12.18 |
| Disease Duration from Onset of Raynaud's Symptoms | 27.3 Months STANDARD_DEVIATION 24.05 | 45.4 Months STANDARD_DEVIATION 9.8 | 19.2 Months STANDARD_DEVIATION 7.44 | 24.7 Months STANDARD_DEVIATION 17.12 | 26.6 Months STANDARD_DEVIATION 17.35 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 1 Participants | 7 Participants | 1 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 2 Participants | 5 Participants | 2 Participants | 13 Participants |
| Region of Enrollment United States | 6 participants | 2 participants | 7 participants | 2 participants | 17 participants |
| Sex: Female, Male Female | 3 Participants | 1 Participants | 6 Participants | 2 Participants | 12 Participants |
| Sex: Female, Male Male | 3 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 2 | 0 / 7 | 0 / 2 | 0 / 13 | 0 / 4 |
| other Total, other adverse events | 6 / 6 | 2 / 2 | 6 / 7 | 0 / 2 | 12 / 13 | 2 / 4 |
| serious Total, serious adverse events | 1 / 6 | 0 / 2 | 2 / 7 | 0 / 2 | 3 / 13 | 0 / 4 |
Outcome results
Primary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through end of study (48 weeks)
Population: The Per Protocol 48 (PP48) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 48 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.400 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.667 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.500 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 proportion of participants |
Comparison: Treatment start to Week 48p-value: 1Fisher Exact
Comparison: Treatment start to Week 48p-value: 0.4Fisher Exact
Primary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through end of study (48 weeks for participants who complete the study)
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.333 Proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 Proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.571 Proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 Proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.462 Proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.000 Proportion of participants |
Comparison: Treatment start to Week 48p-value: 1Fisher Exact
Comparison: Treatment start to Week 48p-value: 0.444Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed
Population: The Per Protocol 12 (PP12) is defined as the treated participants who receive at least 4 of the 5 infusions over the first 12 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 12 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.800 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.500 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.600 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.700 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12 | 0.250 proportion of participants |
Comparison: Treatment start to Week 12p-value: 1Fisher Exact
Comparison: Treatment start to Week 12p-value: 0.429Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 1.000 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 1.000 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 1.000 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.833 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.500 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 1.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.500 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 1.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.857 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.714 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.857 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.429 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.846 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.923 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.923 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.615 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.500 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.250 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.250 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.500 proportion of participants |
Comparison: Treatment start to Week 12p-value: 0.464Fisher Exact
Comparison: Treatment start to Week 12p-value: 0.5Fisher Exact
Comparison: Treatment start to Week 24p-value: 0.25Fisher Exact
Comparison: Treatment start to Week 24p-value: 0.167Fisher Exact
Comparison: Treatment start to Week 36p-value: 0.083Fisher Exact
Comparison: Treatment start to Week 48p-value: 0.083Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Population: The Per Protocol 24 (PP24) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 24 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 1.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 0.500 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 1.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 1.000 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24. | 0.250 proportion of participants |
Comparison: Treatment start to Week 24p-value: 0.286Fisher Exact
Comparison: Treatment start to Week 24p-value: 0.067Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Population: The Per Protocol 36 (PP36) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 36 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 1.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 1.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 1.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 1.000 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36. | 0.500 proportion of participants |
Comparison: Treatment start to Week 36p-value: 0.1Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Population: The Per Protocol 48 (PP48) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 48 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 1.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 1.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 1.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 1.000 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48. | 0.500 proportion of participants |
Comparison: Treatment start to Week 48p-value: 0.1Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through Week 12 study visit or 12 weeks on study if the visit was missed.
Population: The Per Protocol 12 (PP12) is defined as the treated participants who receive at least 4 of the 5 infusions over the first 12 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 12 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.200 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.200 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.200 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12 | 0.000 proportion of participants |
Comparison: Treatment start to Week 12p-value: 1Fisher Exact
Comparison: Treatment start to Week 12p-value: 1Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through Week 12 study visit or 12 weeks on study if the visit was missed. Baseline through Week 24 study visit or 24 weeks on study if the visit was missed. Baseline through Week 36 study visit or 36 weeks on study if the visit was missed
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.333 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.167 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.333 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.000 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.286 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.143 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.429 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.000 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.308 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.154 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.385 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 12 | 0.000 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 36 | 0.000 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Week 24 | 0.000 proportion of participants |
Comparison: Treatment start to Week 12p-value: 1Fisher Exact
Comparison: Treatment start to Week 12p-value: 1Fisher Exact
Comparison: Treatment start to Week 24p-value: 1Fisher Exact
Comparison: Treatment start to Week 24p-value: 1Fisher Exact
Comparison: Treatment start to Week 36p-value: 1Fisher Exact
Comparison: Treatment start to Week 36p-value: 0.5Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through Week 24 study visit or 24 weeks on study if the visit was missed.
Population: The Per Protocol 24 (PP24) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 24 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.400 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.500 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.444 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24. | 0.000 proportion of participants |
Comparison: Treatment start to Week 24p-value: 1Fisher Exact
Comparison: Treatment start to Week 24p-value: 0.467Fisher Exact
Secondary
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through Week 36 study visit or 36 weeks on study if the visit was missed.
Population: The Per Protocol 36 (PP36) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 36 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.400 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.667 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.500 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36. | 0.00 proportion of participants |
Comparison: Treatment start to Week 36p-value: 1Fisher Exact
Comparison: Treatment start to Week 36p-value: 0.4Fisher Exact
Secondary
Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Population: The Per Protocol 48 (PP48) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 48 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.200 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.333 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.250 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
p-value: 1Fisher Exact
Comparison: Treatment start to Week 48p-value: 1Fisher Exact
Secondary
Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.
Time frame: Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.167 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.143 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.154 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy. | 0.000 proportion of participants |
Comparison: Treatment start to Week 48p-value: 1Fisher Exact
Comparison: Treatment start to Week 48p-value: 1Fisher Exact
Secondary
Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed.
Population: The Per Protocol 12 (PP12) is defined as the treated participants who receive at least 4 of the 5 infusions over the first 12 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 12 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12 | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Population: The Per Protocol 24 (PP24) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 24 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24. | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Population: The Per Protocol 36 (PP36) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 36 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36. | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Population: 5 The Per Protocol 48 (PP48) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 48 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48. | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed.
Population: The Per Protocol 12 (PP12) is defined as the treated participants who receive at least 4 of the 5 infusions over the first 12 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 12 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12 | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Population: The safety population is defined as all participants who receive any amount of the placebo or the brentuximab vedotin study drug. Safety population is conceptually equivalent to the standard intent-to-treat population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 24 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 36 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 48 | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48. | Week 12 | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Population: The Per Protocol 24 (PP24) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 24 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24. | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Population: The Per Protocol 36 (PP36) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 36 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36. | 0.0 proportion of participants |
Secondary
Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48.
Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.
Time frame: Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Population: The Per Protocol 48 (PP48) is defined as the treated participants who receive at least 7 of the 8 infusions over the first 21 weeks, and who have no major protocol deviations that would affect the safety outcomes through the first 48 weeks.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 0.6 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |
| 0.6 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |
| 1.2 mg/kg Brentuximab Vedotin | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |
| 1.2 mg/kg Placebo | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |
| Brentuximab Vedotin in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |
| Placebo in Pooled Participants | Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48. | 0.0 proportion of participants |